Skip to main content

Mission BioCapital — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

62
Companies
$1.8B
Total invested
$43.2M
Avg. check
19
Industries
Biotechnology 21Health Care 18Therapeutics 16Medical 9Life Science 4Pharmaceutical 3+13 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 62
GraphWear Technologies
October 2021

Pioneering needle-free disease monitoring

Health Care · San Francisco$20.5M Series B
Symbiome
October 2022

Symbiome offers skincare as nature intended solution which is scientifically and intentionally formulated using ancestral ingredients.

Health Care · San FranciscoVenture - Series Unknown
Enodia Therapeutics
January 2026

Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases.

Biotechnology · Paris$24.2M Seed
EpiBiologics
January 2026

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

Biotechnology · San Mateo$107.0M Series B
Nocion Therapeutics
January 2026

Nocion Therapeutics is a developer of novel pharmaceuticals intended to treat the conditions arising from neurogenic inflammation.

Biotechnology · Cambridge$23.0M Series B
Mediar Therapeutics
January 2026

Mediar is a pre-clinical stage biotechnology company developing therapeutics for the treatment of fibrosis.

Biotechnology · Cambridge$76.0M Series B
AI Proteins
November 2025

AI Proteins is a biotechnology company that focuses on the de novo design and engineering of miniprotein therapeutics.

Artificial Intelligence (AI) · Boston$41.5M Series A
March Biosciences
April 2025

March Biosciences is a clinical-stage cell therapy company that develops CAR-T cell strategies to address hematological cancers.

Biotechnology · Houston$200K Grant
Glycomine
April 2025

Glycomine is an early-stage biotech working on replacement therapies for rare diseases.

Biotechnology · San Carlos$115.0M Series C
Tune Therapeutics
January 2025

Tune Therapeutics is an epigenetic programming platform for the treatment of disease.

Biotechnology · Durham$175.0M Series B
SiteOne Therapeutics
December 2024

SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.

Biotechnology · South San Francisco$100.0M Series C
Alessa Therapeutics
December 2024

Alessa Therapeutics develops localized treatments for solid organ disease.

Biotechnology · San Francisco$15.0M Seed
Nuvig Therapeutics
December 2024

Nuvig Therapeutics is a biotechnology company developing therapies to induce natural mechanisms to restore immune homeostasis.

Biotechnology · Redwood City$161.0M Series B
Jupiter BioVentures
November 2024

Jupiter BioVentures is a creation engine company that focuses on de-risking early-stage projects.

Biotechnology · Delaware City$70.0M Series Unknown
Integrated Biosciences
October 2024

Integrated Biosciences develops next-generation therapeutics.

Biopharma · Redwood City$17.2M Seed
ImmunOs Therapeutics
September 2024

ImmunOs Therapeutics is a clinical-stage biotechnology company.

Biotechnology · Schlieren$11.0M Series C
Circle Pharma
September 2024

Circle Pharma is a biotechnology company creating bioavailable macrocyclic peptide therapeutics that target protein-protein interactions.

Biotechnology · San Francisco$90.0M Series D
Dren Bio
July 2024

Dren Bio focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents.

Biotechnology · Foster City$25.0M Corporate Round
Progentos Therapeutics
May 2024

Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.

Life Science · Watertown$65.0M Series A
Effector Therapeutics
January 2024

Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.

Biotechnology · San Diego$15.0M Post Ipo Equity
Invenio Imaging
June 2023

INVENIO IMAGING is a privately held corporation

Bioinformatics · Menlo ParkNon Equity Assistance
QurAlis
March 2023

QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.

Biotechnology · Cambridge$88.0M Series B
Arkuda Therapeutics
February 2022

Arkuda Therapeutics is a pharmaceutical company.

Biotechnology · Cambridge$64.0M Series B
Shape Therapeutics
July 2021

A biotechnology company developing RNA technologies to shape the future of gene therapy

Biotechnology · Seattle$112.0M Series B

Where Mission BioCapital invests

Biotechnology21
Health Care18
Therapeutics16
Medical9
Life Science4
Pharmaceutical3

About Mission BioCapital's portfolio

How many companies has Mission BioCapital invested in?

Mission BioCapital has invested in 62 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Mission BioCapital invest in?

Mission BioCapital's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 19 different industry categories.

What is Mission BioCapital's largest investment?

Among tracked funding rounds, Tune Therapeutics received $175.0M in a Series B round. Mission BioCapital's total known invested capital is $1.8B.

What is the average investment size for Mission BioCapital?

Mission BioCapital's average investment size is $43.2M across its portfolio of 62 companies.

What are Mission BioCapital's most recent investments?

Recent Mission BioCapital portfolio additions include GraphWear Technologies, Symbiome, Enodia Therapeutics, EpiBiologics, Nocion Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 62 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →